Pharmacological inhibitors of glycogen synthase kinase 3

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Specificity and mechanism of action of some commonly used protein kinase inhibitors

DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132

A molecular mechanism for the effect of lithium on development.

Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301

Protein kinases — the major drug targets of the twenty-first century?

Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186

Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109

GSK-3: tricks of the trade for a multi-tasking kinase

Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084

The glamour and gloom of glycogen synthase kinase-3

Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517

GSK3 takes centre stage more than 20 years after its discovery

FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 6×

Protein Kinase Inhibitors: Insights into Drug Design from Structure

Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198

GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196

Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia

Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M., & Gogos, J. A. (2004) · Nature Genetics · doi:10.1038/ng1296 · Cited by 913

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

Lucas, J. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 900

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897

GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins

Meijer, L., Skaltsounis, A.-L., Magiatis, P., Polychronopoulos, P., Knockaert, M., Leost, M., Ryan, X. P., Vonica, C. A., Brivanlou, A., Dajani, R., et al. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.11.010 · Cited by 808

Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade

Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307921101 · Cited by 793

GSK3 inhibitors: development and therapeutic potential

Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790

Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease

Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723

Crystal Structure of Glycogen Synthase Kinase 3β

Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., & Pearl, L. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00374-9 · Cited by 674

Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418

Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552

Pharmacological inhibitors of cyclin-dependent kinases

Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537

Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo

Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532

The Wnt signaling pathway and its role in tumor development

Lustig, B., & Behrens, J. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0431-0 · Cited by 524

Molecular Targets of Lithium Action

Phiel, C. J., & Klein, P. S. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 515

Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo

Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00259-9 · Cited by 509

Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes

Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500

Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila

Jackson, G. R., Wiedau-Pazos, M., Sang, T.-K., Wagle, N., Brown, C. A., Massachi, S., & Geschwind, D. H. (2002) · Neuron · doi:10.1016/s0896-6273(02)00706-7 · Cited by 488

First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease

Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455

Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent

Meijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454

Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium

Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435

Structure of GSK3beta reveals a primed phosphorylation mechanism.

ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H.-M., Swenson, L. L., & Jain, J. (2001) · Nature Structural Biology · doi:10.1038/89624 · Cited by 407

Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

Polychronopoulos, P., Magiatis, P., Skaltsounis, A.-L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S. M., Pearl, L., Leost, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031016d · Cited by 380

Synthetic small molecules that control stem cell fate

Ding, S., Wu, T. Y. H., Brinker, A., Peters, E. C., Hur, W., Gray, N. S., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0732087100 · Cited by 376

Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25

Leost, M., Schultz, C., Link, A., Wu, Y., Biernat, J., Mandelkow, E., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W., et al. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01673.x · Cited by 376

Regulation and localization of tyrosine216phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration

Bhat, R. V., Shanley, J., Correll, M. P., Fieles, W. E., Keith, R. A., Scott, C. W., & Lee, C.-M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190297597 · Cited by 366

Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10011 · Cited by 333

GBP, an Inhibitor of GSK-3, Is Implicated in Xenopus Development and Oncogenesis

Yost, C., Farr, G. H., Pierce, S. B., Ferkey, D. M., Chen, M. M., & Kimelman, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81208-8 · Cited by 328

Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease

Smith, P. D., Crocker, S. J., Jackson-Lewis, V., Jordan-Sciutto, K. L., Hayley, S., Mount, M. P., O'Hare, M. J., Callaghan, S., Slack, R. S., Przedborski, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232515100 · Cited by 319

Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors

Bertrand, J. A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H. M., & Flocco, M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.031 · Cited by 319

Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex

Dajani, R., Fraser, E., Roe, S. M., Yeo, M., Good, V. M., Thompson, V., Dale, T. C., & Pearl, L. H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg068 · Cited by 315

A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma–associated herpesvirus latency

Fujimuro, M., Wu, F. Y., apRhys, C., Kajumbula, H., Young, D. B., Hayward, G. S., & Hayward, S. D. (2003) · Nature Medicine · doi:10.1038/nm829 · Cited by 307

Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors

Wang, J., Liu, S., Fu, Y., Wang, J. H., & Lu, Y. (2003) · Nature Neuroscience · doi:10.1038/nn1119 · Cited by 279

Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats

Nonaka, S., & Chuang, D.-M. (1998) · NeuroReport · doi:10.1097/00001756-199806220-00031 · Cited by 249

A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin

Thomas, G. M., Frame, S., Goedert, M., Nathke, I., Polakis, P., & Cohen, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01161-8 · Cited by 229

Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats

Cline, G. W., Johnson, K., Regittnig, W., Perret, P., Tozzo, E., Xiao, L., Damico, C., & Shulman, G. I. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2903 · Cited by 228

Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model

Ren, M., Senatorov, V. V., Chen, R.-W., & Chuang, D.-M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937423100 · Cited by 206

Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle

Nikoulina, S. E., Ciaraldi, T. P., Mudaliar, S., Carter, L., Johnson, K., & Henry, R. R. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2190 · Cited by 198

Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington’s Disease Mutation

Carmichael, J., Sugars, K. L., Bao, Y. P., & Rubinsztein, D. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204861200 · Cited by 195

1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β

Kunick, C., Lauenroth, K., Leost, M., Meijer, L., & Lemcke, T. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.062 · Cited by 179

Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3β and attenuated by lithium

King, T. D., Bijur, G. N., & Jope, R. S. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03005-0 · Cited by 177

3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)

Smith, D. G., Buffet, M., Fenwick, A. E., Haigh, D., Ife, R. J., Saunders, M., Slingsby, B. P., Stacey, R., & Ward, R. W. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00721-6 · Cited by 161

Inhibition of glycogen synthase kinase-3β by bivalent zinc ions: insight into the insulin-mimetic action of zinc

Ilouz, R., Kaidanovich, O., Gurwitz, D., & Eldar-Finkelman, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00636-8 · Cited by 160

Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes

Wagman, A., Johnson, K., & Bussiere, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452668 · Cited by 153 · cited 1×

Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3

Plotkin, B., Kaidanovich‐Beilin, O., Talior‐Volodarsky, I., & Eldar-Finkelman, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047381 · Cited by 151

A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment

Wakefield, J. G., Stephens, D. J., & Tavaré, J. M. (2003) · Journal of Cell Science · doi:10.1242/jcs.00273 · Cited by 147

Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects

Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M. E. M., Endicott, J., VIERFOND, J. ‐., & Meijer, L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020319p · Cited by 146

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

Lane, M. E., Yu, B., Rice, A. G., Lipson, K. E., Liang, C., Sun, L., Tang, C., McMahon, G., Pestell, R. G., & Wadler, S. (2001) · PubMed · Cited by 145

Intracellular Targets of Paullones

Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C., & Meijer, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202651200 · Cited by 144

The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31‐8220) are potent inhibitors of glycogen synthase kinase‐3 activity

Hers, I., Tavaré, J. M., & Denton, R. M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01389-7 · Cited by 144

Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments

Gould, T. D., & Manji, H. K. (2006) · Wiley eBooks · doi:10.1002/0470052171.ch7 · Cited by 134

Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors

Droucheau, E., Primot, A., Thomas, V., Mattei, D., Knockaert, M., Richardson, C. D., Sallicandro, P., Alano, P., Jafarshad, A., Baratte, B., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.023 · Cited by 118

Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.

Liao, X., Zhang, L., Thrasher, J. B., Du, J., & Li, B. (2003) · PubMed · Cited by 114

Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment

Cohen, Y., Chetrit, A., Cohen, Y., Sirota, P., & Modan, B. (1998) · Medical Oncology · doi:10.1007/bf02787342 · Cited by 109

Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats

Henriksen, E. J., Kinnick, T. R., Teachey, M. K., O'Keefe, M. P., Ring, D., Johnson, K. W., & Harrison, S. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00346.2002 · Cited by 108

5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)

Witherington, J. J., Bordas, V., Haigh, D., Hickey, D. M. B., Ife, R. J., Rawlings, A. D., Slingsby, B. P., Smith, D. G., & Ward, R. W. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00135-5 · Cited by 108

Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3

Pérez, M., Rojo, A. I., Wandosell, F. G., Díaz‐Nido, J., & Ávila, J. (2003) · Biochemical Journal · doi:10.1042/bj20021596 · Cited by 106

Simultaneous inhibition of GSK3α and GSK3β using hairpin siRNA expression vectors

Yu, J., Taylor, J., DeRuiter, S. L., Vojtek, A. B., & Turner, D. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00037-0 · Cited by 105

Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei

Iwahana, E., Akiyama, M., Miyakawa, K., Uchida, A., Kasahara, J., Fukunaga, K., Hamada, T., & Shibata, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03322.x · Cited by 103

Thienyl and Phenyl α-Halomethyl Ketones: New Inhibitors of Glycogen Synthase Kinase (GSK-3β) from a Library of Compound Searching

Conde, S., Pérez, D. I., Martínez, A., Pérez, C., & Moreno, F. J. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034108b · Cited by 103

Akt/GSK3β serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations

Ryder, J. W., Yuan, S., & Ni, B. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.07.004 · Cited by 92

6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)

Witherington, J. J., Bordas, V., Gaiba, A., Naylor, A., Rawlings, A. D., Slingsby, B. P., Smith, D. G., Takle, A. K., & Ward, R. W. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00646-2 · Cited by 91

GSK‐3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β‐catenin stabilisation without elevation of glycogen synthase activity

Culbert, A. A., Brown, M. J. B., Frame, S., Hagen, T., Cross, D. A. E., Bax, B. D., & Reith, A. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02990-8 · Cited by 85

Synthesis and Discovery of Macrocyclic Polyoxygenated Bis-7-azaindolylmaleimides as a Novel Series of Potent and Highly Selective Glycogen Synthase Kinase-3β Inhibitors

Kuo, G., Prouty, C. P., DeAngelis, A., Shen, L., O’Neill, D. J., Shah, C. R., Connolly, P. J., Murray, W. V., Conway, B. R., Cheung, P., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030115o · Cited by 83

Glucose-Induced Expression of the Cyclin-Dependent Protein Kinase 5 Activator p35 Involved in Alzheimer’s Disease Regulates Insulin Gene Transcription in Pancreatic β-Cells

Ubeda, M., Kemp, D. M., & Habener, J. F. (2004) · Endocrinology · doi:10.1210/en.2003-1522 · Cited by 80

Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors

Nærum, L., Nørskov‐Lauritsen, L., & Olesen, P. H. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00169-5 · Cited by 66

Use of lithium and SB‐415286 to explore the role of glycogen synthase kinase‐3 in the regulation of glucose transport and glycogen synthase

MacAulay, K., Hajduch, É., Blair, A. S., Coghlan, M. P., Smith, S. A., & Hundal, H. S. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03777.x · Cited by 63

Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice

Gould, T. D. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00096-3 · Cited by 59

Glycogen synthase kinase-3 as drug target: From wallflower to center of attention

Wauwe, J. V., & Haefner, B. (2003) · Drug News & Perspectives · doi:10.1358/dnp.2003.16.9.829337 · Cited by 59

Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3

Zhang, H., White, K. B., Ye, H., McComsey, D. F., Derian, C. K., Addo, M. F., Andrade‐Gordon, P., Eckardt, A. J., Conway, B. R., Westover, L., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00644-9 · Cited by 57

Novel GSK-3 inhibitors with improved cellular activity

Peat, A. J., Garrido, D. M., Boucheron, J. A., Schweiker, S. L., Dickerson, S. H., Wilson, J. R., Wang, T. Y., & Thomson, S. A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.037 · Cited by 54

Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

Eldar-Finkelman, H., & Ilouz, R. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.9.1511 · Cited by 52

Mental plaque removal

Strooper, B. D., & Woodgett, J. R. (2003) · Nature · doi:10.1038/423392a · Cited by 51

Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors

Ortega, M. A., Romero-Montoya, M. E., Zarranz, B., Jaso, A., Aldana, I., Leclerc, S., Meijer, L., & Monge, A. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00069-x · Cited by 41

Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors

Shen, L., Prouty, C. P., Conway, B. R., Westover, L., Xu, J., Look, R. A., Chen, X., Beavers, M. P., Roberts, J. R., Murray, W. V., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.09.047 · Cited by 36

CDK versus GSK-3 Inhibition

Fischer, P. M. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.12.009 · Cited by 34

P24, a glycogen synthase kinase 3 (GSK 3) inhibitor

Martı́n, C. P., Vázquez, J., Ávila, J., & Moreno, F. J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00092-8 · Cited by 29

CK1 and GSK3 in the Drosophila and Mammalian Circadian Clock

Harms, E., Young, M. W., & Saez, L. (2003) · Novartis Foundation Symposia · doi:10.1002/0470090839.ch19 · Cited by 27

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031

SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner

Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759

Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1

Zhou, X., Yu, S., Zhao, D.-M., Harty, J. T., Badovinac, V. P., & Xue, H.-H. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.002 · Cited by 688

Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder

Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404

A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320